Last reviewed · How we verify
Benserazide Only Product
Benserazide Only Product is a Small molecule drug developed by Phoenicia BioScience. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Benserazide Only Product |
|---|---|
| Sponsor | Phoenicia BioScience |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The BENeFiTS Trial in Beta Thalassemia Intermedia (PHASE1, PHASE2)
- Relative Bioavailability Study of HRG2010 in Healthy Subjects (PHASE1)
- Molecular Basis of Loss Aversion (NA)
- Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission (EARLY_PHASE1)
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg (PHASE1)
- Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke (PHASE3)
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide (PHASE1)
- Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benserazide Only Product CI brief — competitive landscape report
- Benserazide Only Product updates RSS · CI watch RSS
- Phoenicia BioScience portfolio CI
Frequently asked questions about Benserazide Only Product
What is Benserazide Only Product?
Who makes Benserazide Only Product?
What development phase is Benserazide Only Product in?
Related
- Manufacturer: Phoenicia BioScience — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing